

Figure 1. U.S. and U.K. Colonoscopy Surveillance Guidelines according to Risk Group.

Participants in the pooled studies required one or more adenoma(s) to be eligible. LGD, low-grade dysplasia; HGD, high grade dysplasia.

Supplemental Figure 1. Advanced neoplasia at a one-year colonoscopy according to U.S. (1a) and U.K. (1b) risk groups, stratified by study trial arms. APPS, Antioxidant Polyp Prevention Study; CPPS, Calcium Polyp Prevention Study; PPT, Polyp Prevention Trial; WBF, Wheat Bran Fiber trial; BC, beta carotene; Vit C, vitamin C.

Supplemental Figure 2. Patients classified by U.S. Colonoscopy Surveillance Risk Groups (6, 9)reclassified according to U.K. Colonoscopy Surveillance Risk Groups (7, 8), with corresponding surveillance intervals and absolute risk of advanced neoplasms and high-grade dysplasia/colorectal cancer (HGD/CRC) found at colonoscopy one year post-polypectomy (N=3226). Advanced neoplasia is defined as one or more of the following: large adenoma (≥ 1 cm), presence of high-grade dysplasia, adenoma with tubulovillous or villous histology, or colorectal cancer. *Percent (95% confidence intervals).

Supplemental Table 1. Comparison of participants included to those excluded by primary reason for exclusion*

| | Included (n=3226) | | Excluded (n=2076) | | Excluded, no 6-18 month colonoscopy* (n=1283) | | Excluded, not classifiable* (n=790) | |
|-------------------------|----------------------|--------|----------------------|--------|--|--------|---|--------|
| | No. | (%) | No. | (%) | No. | (%) | No. | (%) |
| Age, years | | | | | | | | |
| <50 | 325 | (10.1) | 262 | (12.6) | 168 | (13.1) | 94 | (11.9) |
| 50-59 | 765 | (23.7) | 551 | (26.5) | 342 | (26.7) | 209 | (26.5) |
| 60-69 | 1317 | (40.8) | 784 | (37.8) | 449 | (35.0) | 333 | (42.2) |
| 70+ | 819 | (25.4) | 479 | (23.1) | 324 | (25.3) | 154 | (19.5) |
| Sex | | | | | | | | |
| Women | 974 | (30.2) | 674 | (32.5) | 433 | (33.7) | 241 | (30.5) |
| Men | 2252 | (69.8) | 1402 | (67.5) | 850 | (66.3) | 549 | (69.5) |
| Family history of CRC | | | | | | | | |
| No | 2357 | (73.1) | 1483 | (71.4) | 942 | (73.4) | 538 | (68.1) |
| Yes | 686 | (21.3) | 428 | (20.6) | 248 | (19.3) | 180 | (22.8) |
| Unknown | 183 | (5.7) | 165 | (7.9) | 93 | (7.2) | 72 | (9.1) |
| Previous Polyp | | | | | | | | |
| No | 2382 | (73.8) | 1475 | (71.1) | 928 | (72.3) | 544 | (68.9) |
| Yes | 711 | (22.0) | 557 | (26.8) | 326 | (25.4) | 231 | (29.2) |
| Unknown | 133 | (4.1) | 44 | (2.1) | 29 | (2.3) | 15 | (1.9) |
| Number of adenomas | | | | | | | | |
| 1 | 1839 | (57.0) | 1389 | (66.9) | 823 | (64.1) | 564 | (71.4) |
| 2 | 693 | (21.5) | 463 | (22.3) | 259 | (20.2) | 203 | (25.7) |
| 3+ | 694 | (21.5) | 203 | (9.8) | 193 | (15.0) | 10 | (1.3) |
| Unknown | 0 | (0.0) | 21 | (1.0) | 8 | (0.6) | 13 | (1.6) |
| Adenoma location | | | | | | | | |
| Distal/Rectal only | 1669 | (51.7) | 1082 | (52.1) | 665 | (51.8) | 414 | (52.4) |
| Proximal only | 796 | (24.7) | 633 | (30.5) | 349 | (27.2) | 284 | (35.9) |
| Proximal and Distal | 698 | (21.6) | 291 | (14.0) | 225 | (17.5) | 66 | (8.4) |
| Unknown | 63 | (2.0) | 70 | (3.4) | 44 | (3.4) | 26 | (3.3) |
| Size of largest adenoma | | | | | | | | |
| <10mm | 1830 | (56.7) | 1524 | (73.4) | 844 | (65.8) | 680 | (86.1) |
| 10 to <20mm | 1098 | (34.0) | 304 | (14.6) | 303 | (23.6) | 0 | (0.0) |
| 20+ mm | 296 | (9.2) | 66 | (3.2) | 64 | (5.0) | 0 | (0.0) |
| Unknown | 2 | (0.1) | 182 | (8.8) | 72 | (5.6) | 110 | (13.9) |
| Histology | | | | | | | | |
| Tubular | 2073 | (64.3) | 1350 | (65.0) | 816 | (63.6) | 534 | (67.6) |
| TV/Villous | 990 | (30.7) | 286 | (13.8) | 273 | (21.3) | 13 | (1.6) |
| CRC | 0 | (0.0) | 3 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Undecided/Other | 163 | (5.1) | 437 | (21.1) | 194 | (15.1) | 243 | (30.8) |

| | | | | | | | | |
|----------------------|------|--------|------|--------|------|--------|-----|--------|
| High grade dysplasia | | | | | | | | |
| No | 2476 | (76.8) | 1406 | (67.7) | 1092 | (85.1) | 313 | (39.6) |
| Yes | 342 | (10.6) | 148 | (7.1) | 143 | (11.1) | 3 | (0.4) |
| Not reported | 408 | (12.6) | 522 | (25.1) | 48 | (3.7) | 474 | (60.0) |
| Study | | | | | | | | |
| APPS | 758 | (23.5) | 106 | (5.1) | 87 | (6.8) | 18 | (2.3) |
| CPPS | 408 | (12.6) | 522 | (25.1) | 48 | (3.7) | 474 | (60.0) |
| PPT | 1180 | (36.6) | 899 | (43.3) | 728 | (56.7) | 171 | (21.6) |
| WBF | 880 | (27.3) | 549 | (26.4) | 420 | (32.7) | 127 | (16.1) |

Abbreviations: CRC, colorectal cancer; TV, tubulovillous; APPS, Antioxidant Polyp Prevention Study; CPPS, Calcium Polyp Prevention Study; PPT, Polyp Prevention Trial; WBF, Wheat Bran Fiber trial.

* In addition, 3 patients with invasive cancer at baseline were excluded.